Ophthalmic Market Research
Eye diseases are common worldwide, with expanding patient populations. Thus, ophthalmology as a medical branch is on a steady growth to develop related therapy and drugs in the eye-care domain, with a view to offer relief to suffering patients.
Research findings reveal that the global ophthalmic therapeutic market was valued at $15.5 billion in 2009, exhibiting a growth rate of more than 21⁄2 times that of the overall pharmaceutical industry. The sector is expected to continue to grow through 2014 to $20.6 billion, a compound annual growth rate (CAGR) of 5.9%.
As a segment, glaucoma recorded $5.8 billion in 2009 revenue. Six leading glaucoma products are likely to come off patent before 2012, resulting in a compound annual growth rate (CAGR) of 3.6% and estimated revenues of $6.6 billion in 2014.
The Ophthalmic drug therapy market research report provides insight into the pipeline status of ophthalmic therapeutics by company and by stage, as well as a summary of the latest news and developments in this area. In addition to new developments and disease specific pipeline projects, the listed reports also contain extensive information in tabular format on a company’s full product pipeline, and products by phase of development with regard to the therapy area. The study also helps in keeping track of the industry-specific competitors and partners by better understanding their product pipeline.
The study basically aims at providing a comprehensive overview of the on-goings of the ophthalmic therapeutics market.
